Literature DB >> 10506700

Clinical features of patients with stage IIIB and IV bronchioloalveolar carcinoma of the lung.

O S Breathnach1, N Ishibe, J Williams, R I Linnoila, N Caporaso, B E Johnson.   

Abstract

BACKGROUND: The incidence of bronchioloalveolar carcinoma of the lung (BAC), a pathologically distinct type of nonsmall cell lung carcinoma (NSCLC), appears to be rising. In this study, the authors compared data on the clinical presentation and clinical courses of patients with Stage IIIB and IV BAC with data on other types of NSCLC.
METHODS: The authors collected clinical, radiographic, and pathology information about 28 patients with Stage IIIB and IV BAC and 124 patients with other histologic types of NSCLC.
RESULTS: Twelve of 28 BAC patients (43%) were women, compared with 40 of 124 control patients (32%). Nine (32%) of the patients with BAC had never smoked cigarettes, versus 20 controls (16%) (P = 0.02). Eighteen patients (64%) with BAC had bilateral multilobar or multicentric pulmonary involvement, compared with 13 controls (15%) (P < 0.001). Patients with advanced stage (IIIB and IV) BAC had a median survival of 15 months from the time of diagnosis; for patients with other types of Stage IIIB and IV NSCLC, had a median survival of 10 months (P = 0.01).
CONCLUSIONS: Patients with BAC of the lung have clinical, radiographic, and pathologic characteristics that distinguish them from patients with other types of NSCLC. A greater proportion of women and nonsmokers present with BAC than with other types of NSCLC. Patients with advanced stage BAC are more likely to have bilateral diffuse pulmonary involvement, are less likely to develop brain metastases, and have longer survival than patients with other types of Stage IIIB and IV NSCLC. Further research is warranted to define etiology, molecular abnormalities, and more effective therapeutic interventions. Copyright 1999 American Cancer Society.

Entities:  

Mesh:

Year:  1999        PMID: 10506700     DOI: 10.1002/(sici)1097-0142(19991001)86:7<1165::aid-cncr10>3.0.co;2-9

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504).

Authors:  Suresh S Ramalingam; Ju-Whei Lee; Chandra P Belani; Seena C Aisner; Jill Kolesar; Craig Howe; Mario R Velasco; Joan H Schiller
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

2.  Recurrent "pneumonia" in left lower lobe lasting for 8 years: a case report.

Authors:  Dong-Mei Yuan; Yan-Wen Yao; Qian Li; Chen-Yang Liu; Pei Li; E-Hong Cao; Xin-Wu Xiao; Xin Su; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2016-06

3.  Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003).

Authors:  Suresh S Ramalingam; Angela M Davies; Jeffrey Longmate; Martin J Edelman; Primo N Lara; Everett E Vokes; Miguel Villalona-Calero; Barbara Gitlitz; Karen Reckamp; Ravi Salgia; John J Wright; Chandra P Belani; David R Gandara
Journal:  J Thorac Oncol       Date:  2011-10       Impact factor: 15.609

4.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.

Authors:  A Bhattacharjee; W G Richards; J Staunton; C Li; S Monti; P Vasa; C Ladd; J Beheshti; R Bueno; M Gillette; M Loda; G Weber; E J Mark; E S Lander; W Wong; B E Johnson; T R Golub; D J Sugarbaker; M Meyerson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-13       Impact factor: 11.205

Review 5.  Emerging approaches to advanced bronchioloalveolar carcinoma.

Authors:  Howard West
Journal:  Curr Treat Options Oncol       Date:  2006-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.